Germany · Delayed Price · Currency is EUR SUSS MicroTec SE Earnings Call Transcripts
Fiscal Year 2026
-
Record Q1 order intake broke seasonal trends, with strong demand across regions and segments. Revenue and profitability were down as expected, but order momentum remains robust, supporting full-year guidance and improved visibility into 2027.
-
The company reported record sales in 2025, driven by strong demand in Asia and AI-related markets, but expects a slight sales decline in 2026 as order intake timing remains key. Major product launches are planned for late 2026 and 2027, supporting long-term growth and margin expansion ambitions through 2030.
Fiscal Year 2025
-
Record revenue of EUR 503 million in 2025 was achieved, with strong Q4 order intake reversing earlier declines. 2026 is expected to be a transition year with lower sales and margins, but new product launches and continued R&D investment are set to drive growth and margin improvement from 2027.
-
Ambitious growth targets include €750–900 million sales and 43–45% gross margin by 2030, driven by new product launches, service expansion, and increased R&D. Key focus areas are wafer cleaning, hybrid bonding, and modularization, with a strong push into Asia and a shift toward higher-margin services.
-
Nine-month sales reached EUR 384 million with margin pressure leading to revised guidance, but Q4 orders are expected to rebound above EUR 100 million. CapEx peaked due to Taiwan expansion, and Free Cash Flow is targeted to turn positive by year-end. AI and HBM demand are key growth drivers.
-
Q3 saw declining order intake and sales, with gross profit margin dropping to 33.1% due to margin pressure from costs and product mix. Guidance for FY 2025 was lowered for margins, but sales targets remain. Cost-saving measures are underway, and Q4 order intake is expected to improve.
-
Record H1 sales of EUR 266.4 million were achieved, up 38.2% year-over-year, but order intake fell 13.2% amid market uncertainty and AI sector saturation. Gross margin declined due to one-offs and ramp-up costs, while full-year guidance was maintained with a downward margin revision.
-
Q1 2025 delivered strong sales growth and robust order book visibility, with both segments contributing and the new Taiwan site set to double capacity. Margins were impacted by product mix and ramp-up costs, but full-year guidance is confirmed despite increased macroeconomic risks.
Fiscal Year 2024
-
Record sales and profitability were achieved in 2024, with strong growth in both main segments and robust cash flow. 2025 guidance anticipates continued growth, though margins will be impacted by one-off transformation costs and new site investments.
-
H1 2024 delivered robust growth with sales up 45.6%, gross margin at 39.8%, and EBIT margin at 15.6%. Guidance was raised for all key metrics, supported by a strong order book and high demand in core segments, especially in Asia.